272 related articles for article (PubMed ID: 33733969)
1. Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population.
Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
Curr Med Res Opin; 2021 Jun; 37(6):881-890. PubMed ID: 33733969
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US).
Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
Adv Ther; 2021 Jul; 38(7):3771-3788. PubMed ID: 34031859
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population.
Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
J Med Econ; 2021; 24(1):550-562. PubMed ID: 33910464
[TBL] [Abstract][Full Text] [Related]
4. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Lip GY; Keshishian A; Kamble S; Pan X; Mardekian J; Horblyuk R; Hamilton M
Thromb Haemost; 2016 Oct; 116(5):975-986. PubMed ID: 27538358
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
Lip GYH; Keshishian A; Kang A; Luo X; Atreja N; Zhang Y; Schuler P; Jiang J; Yuce H; Deitelzweig S
J Thromb Thrombolysis; 2022 Jul; 54(1):33-46. PubMed ID: 35579733
[TBL] [Abstract][Full Text] [Related]
6. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes.
Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
J Diabetes Complications; 2021 Nov; 35(11):108029. PubMed ID: 34538715
[TBL] [Abstract][Full Text] [Related]
9. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy.
Alberts MJ; He J; Kharat A; Ashton V
Am J Cardiovasc Drugs; 2022 Jul; 22(4):425-436. PubMed ID: 35092000
[TBL] [Abstract][Full Text] [Related]
11. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
[TBL] [Abstract][Full Text] [Related]
12. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
[TBL] [Abstract][Full Text] [Related]
13. A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation-A Single-centre Retrospective Cohort Study in Singapore.
Tiew WJ; Wong VL; Tan VH; Tan YC; Lee EM
Ann Acad Med Singap; 2020 Nov; 49(11):838-847. PubMed ID: 33381777
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
15. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
Lip GY; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Bruno A; Phatak H
Int J Clin Pract; 2016 Sep; 70(9):752-63. PubMed ID: 27550177
[TBL] [Abstract][Full Text] [Related]
16. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study.
Lip GYH; Keshishian AV; Kang AL; Dhamane AD; Luo X; Li X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Di Fusco M; Garcia Reeves AB; Yuce H; Deitelzweig S
J Intern Med; 2021 Jan; 289(1):42-52. PubMed ID: 32602228
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
18. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population.
Berger JS; Ashton V; Laliberté F; Germain G; Bookhart B; Lejeune D; Boudreau J; Lefebvre P; Weir MR
Adv Ther; 2023 Mar; 40(3):1224-1241. PubMed ID: 36658454
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
